길랭 바레 증후군 시장 규모, 점유율, 동향 분석 보고서 : 치료법별, 유형별, 투여 경로별, 유통 채널별, 지역별, 부문 예측(2025-2030년)

Guillain-Barre Syndrome Market Growth & Trends:

The global guillain-Barre syndrome market size is anticipated to reach USD 1.03 billion by 2030 and is expected to expand at a CAGR of 6.10% during the forecast period, according to a new report by Grand View Research, Inc. The increasing prevalence of Guillain-Barre Syndrome (GBS), a rare but serious autoimmune disorder affecting the peripheral nervous system, is driving growth opportunities in the healthcare sector. Businesses can capitalize on this market expansion through advancements in treatment modalities, diagnostic tools, and patient care solutions. The demand for effective therapies such as Intravenous Immunoglobulin (IVIG) and Plasma Exchange is rising, necessitating improved access to these treatments via hospital and retail pharmacies.

GBS presents in multiple variants, each requiring specialized medical approaches. Acute Inflammatory Demyelinating Polyneuropathy (AIDP) is the most common form in North America and Europe, characterized by progressive muscle weakness and sensory disturbances. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP), a related but chronic condition, necessitates long-term management strategies, creating sustained demand for therapeutic interventions. Miller Fisher Syndrome (MFS), a rarer variant, primarily affects eye movement and coordination, necessitating targeted neurological treatments. Acute Motor Axonal Neuropathy (AMAN), more prevalent in Asia and Latin America, underscores the need for region-specific diagnostic and therapeutic developments.

Recent outbreaks of GBS, potentially linked to viral infections such as Zika and other emerging pathogens, have intensified market interest. A surge in cases drives the need for enhanced surveillance, early diagnosis, and timely therapeutic intervention, boosting investment in healthcare infrastructure. Governments and pharmaceutical companies are increasing research efforts to develop new treatment options and improve existing protocols. The outbreak-driven demand for IVIG and Plasma Exchange, primary treatments for GBS, has put pressure on global plasma supply chains, encouraging innovation in alternative therapies.

The COVID-19 pandemic has further impacted the GBS market, as studies have indicated a potential association between SARS-CoV-2 infection and an increased risk of GBS. The surge in COVID-19 cases led to a rise in reported GBS diagnoses, driving higher demand for IVIG and Plasma Exchange treatments. In addition, pandemic-related disruptions in healthcare supply chains have affected the availability of essential therapies, necessitating strategic adjustments in pharmaceutical production and distribution. Increased awareness and research into post-viral neurological complications have also propelled investment into GBS diagnostics and treatment innovations.

Treatment delivery methods are evolving, with both parenteral and oral options under exploration. While IVIG remains the gold standard for acute cases, research into oral immunomodulatory treatments is gaining momentum, potentially offering more accessible long-term management solutions for CIDP patients. Pharmacies play a crucial role in GBS treatment distribution. Hospital pharmacies dominate the market due to the need for inpatient care and close monitoring during IVIG or Plasma Exchange therapy. However, retail pharmacies are expanding their role in CIDP management, providing patients with convenient access to maintenance therapies and supportive medications.

With increasing awareness, evolving treatment approaches, and growing pharmaceutical investment, the GBS market is poised for significant growth. Innovations in both acute and chronic care solutions will continue to shape the landscape, creating new opportunities for businesses in healthcare, therapeutics.

Guillain-Barre Syndrome Market Report Highlights:

• Intravenous Immunoglobulin (IVIG) dominated the Guillain-Barre Syndrome (GBS) treatment market in 2024. This dominance is driven by IVIG's proven efficacy in modulating the immune response, reducing disease progression, and improving recovery rates, making it the preferred first-line treatment for GBS.
• Acute Inflammatory Demyelinating Polyneuropathy (AIDP) held the largest market share among GBS subtypes in 2024. As the most common form of GBS, particularly in North America and Europe, AIDP's prevalence significantly influences the demand for effective therapeutic options, further strengthening its market dominance.
• Parenteral led the GBS treatment market in 2024. Given the critical nature of the disease, IV-administered treatments such as IVIG and plasma exchange ensure rapid and effective therapeutic action, enhancing patient outcomes in both acute and severe cases.
• Hospital pharmacies remained the dominant distribution channel in 2024. Due to the need for immediate medical intervention and specialized care, hospital pharmacies play a crucial role in ensuring the availability and administration of GBS treatments, particularly in acute care settings.
• North America led the GBS treatment market, attributed to factors such as a well-established healthcare infrastructure, high awareness of neurological disorders, and the availability of advanced treatment options. The region's strong focus on research and innovation further supports market growth.

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Guillain-Barre Syndrome (GBS) Market Variables, Trends, & Scope

• 3.1. Parent Market Outlook
• 3.2. Ancillary Market Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Increasing prevalence of Guillain-Barre Syndrome (GBS)
    • 3.3.1.2. Government regulations and guidelines
    • 3.3.1.3. Advancements in treatment options
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. Side effects and adverse reactions
    • 3.3.2.2. High cost treatment
• 3.4. Guillain-Barre Syndrome Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape

Chapter 4. Guillain-Barre Syndrome (GBS) Market: By Therapeutics Estimates & Trend Analysis

• 4.1. Guillain-Barre Syndrome Market: Therapeutics Segment Dashboard
• 4.2. Guillain-Barre Syndrome Market: By Therapeutics Movement Analysis, 2024 & 2030 (USD Million)
• 4.3. Intravenous Immunoglobulin (IVIG)
  • 4.3.1. Intravenous Immunoglobulin (IVIG) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Plasma Exchange
  • 4.4.1. Plasma Exchange Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Others
  • 4.5.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Guillain-Barre Syndrome (GBS) Market: By Therapeutics Estimates & Trend Analysis

• 5.1. Guillain-Barre Syndrome Market: Therapeutics Segment Dashboard
• 5.2. Guillain-Barre Syndrome Market: By Therapeutics Movement Analysis, 2024 & 2030 (USD Million)
• 5.3. Acute Inflammatory Demyelinating Polyneuropathy (AIDP)
  • 5.3.1. Acute Inflammatory Demyelinating Polyneuropathy (AIDP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
  • 5.4.1. Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Miller Fisher Syndrome (MFS)
  • 5.5.1. Miller Fisher Syndrome (MFS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Acute Motor Axonal Neuropathy (AMAN)
  • 5.6.1. Acute Motor Axonal Neuropathy (AMAN) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.7. Other
  • 5.7.1. Other Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Guillain- Barre Syndrome (GBS) Market: Route of Administration Estimates & Trend Analysis

• 6.1. Guillain-Barre Syndrome Market: Route of Administration Segment Dashboard
• 6.2. Guillain-Barre Syndrome Market: By Route of Administration Movement Analysis, 2024 & 2030 (USD Million)
• 6.3. Parenteral
  • 6.3.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Oral
  • 6.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Guillain Barre Syndrome (GBS) Market: Distribution Channel Estimates & Trend Analysis

• 7.1. Guillain-Barre Syndrome Market: Distribution Channel Segment Dashboard
• 7.2. Guillain-Barre Syndrome Market: Distribution Channel Movement Analysis, 2024 & 2030 (USD Million)
• 7.3. Hospital Pharmacies
  • 7.3.1. Hospital Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Retail Pharmacies
  • 7.4.1. Retail Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Other Pharmacies
  • 7.5.1. Other Pharmacies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Guillain-Barre Syndrome (GBS) Market: Regional Estimates & Trend Analysis

• 8.1. Guillain-Barre Syndrome Market Share, By Region, 2024 & 2030, USD Million
• 8.2. North America
  • 8.2.1. North America Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.2. U.S.
    • 8.2.2.1. U.S. Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.3. Canada
    • 8.2.3.1. Canada Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.2.4. Mexico
    • 8.2.4.1. Mexico Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.3. Europe
  • 8.3.1. Europe Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.2. UK
    • 8.3.2.1. UK Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.3. Germany
    • 8.3.3.1. Germany Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.4. France
    • 8.3.4.1. France Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.5. Italy
    • 8.3.5.1. Italy Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.6. Spain
    • 8.3.6.1. Spain Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.7. Denmark
    • 8.3.7.1. Denmark Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.8. Norway
    • 8.3.8.1. Norway Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.3.9. Sweden
    • 8.3.9.1. Sweden Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.4. Asia Pacific
  • 8.4.1. Asia Pacific Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. China
    • 8.4.2.1. China Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Japan
    • 8.4.3.1. Japan Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. India
    • 8.4.4.1. India Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.5. South Korea
    • 8.4.5.1. South Korea Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.6. Australia
    • 8.4.6.1. Australia Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.7. Thailand
    • 8.4.7.1. Thailand Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Latin America
  • 8.5.1. Latin America Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. Brazil
    • 8.5.2.1. Brazil Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Argentina
    • 8.5.3.1. Argentina Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Middle East and Africa
  • 8.6.1. Middle East and Africa Guillain-Barre Syndrome Market Estimates and Forecasts, 2017 - 2030 (USD Million)
  • 8.6.2. Saudi Arabia
    • 8.6.2.1. Saudi Arabia Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. UAE
    • 8.6.3.1. UAE Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. Kuwait
    • 8.6.4.1. Kuwait Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. South Africa
    • 8.6.5.1. South Africa Guillain-Barre Syndrome Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Recent Developments & Impact Analysis by Key Market Participants
• 9.2. Company Categorization
• 9.3. Company Market Share Analysis, 2024
• 9.4. Company Heat Map Analysis, 2024
• 9.5. Company Profiles
  • 9.5.1. AbbVie Inc.
    • 9.5.1.1. Participant's Overview
    • 9.5.1.2. Financial Performance
    • 9.5.1.3. Product Benchmarking
    • 9.5.1.4. Recent Developments/ Strategic Initiatives
  • 9.5.2. Biogen
    • 9.5.2.1. Participant's Overview
    • 9.5.2.2. Financial Performance
    • 9.5.2.3. Product Benchmarking
    • 9.5.2.4. Recent Developments/ Strategic Initiatives
  • 9.5.3. Cadila Pharmaceuticals
    • 9.5.3.1. Participant's Overview
    • 9.5.3.2. Financial Performance
    • 9.5.3.3. Product Benchmarking
    • 9.5.3.4. Recent Developments/ Strategic Initiatives
  • 9.5.4. CSL
    • 9.5.4.1. Participant's Overview
    • 9.5.4.2. Financial Performance
    • 9.5.4.3. Product Benchmarking
    • 9.5.4.4. Recent Developments/ Strategic Initiatives
  • 9.5.5. F. Hoffmann-La Roche Ltd.
    • 9.5.5.1. Participant's Overview
    • 9.5.5.2. Financial Performance
    • 9.5.5.3. Product Benchmarking
    • 9.5.5.4. Recent Developments/ Strategic Initiatives
  • 9.5.6. GSK plc.
    • 9.5.6.1. Participant's Overview
    • 9.5.6.2. Financial Performance
    • 9.5.6.3. Product Benchmarking
    • 9.5.6.4. Recent Developments/ Strategic Initiatives
  • 9.5.7. Grifols S.A.
    • 9.5.7.1. Participant's Overview
    • 9.5.7.2. Financial Performance
    • 9.5.7.3. Product Benchmarking
    • 9.5.7.4. Recent Developments/ Strategic Initiatives
  • 9.5.8. LGM Pharma.
    • 9.5.8.1. Participant's Overview
    • 9.5.8.2. Financial Performance
    • 9.5.8.3. Product Benchmarking
    • 9.5.8.4. Recent Developments/ Strategic Initiatives
  • 9.5.9. Merck & Co., Inc.
    • 9.5.9.1. Participant's Overview
    • 9.5.9.2. Financial Performance
    • 9.5.9.3. Product Benchmarking
    • 9.5.9.4. Recent Developments/ Strategic Initiatives
  • 9.5.10. Octapharma AG
    • 9.5.10.1. Participant's Overview
    • 9.5.10.2. Financial Performance
    • 9.5.10.3. Product Benchmarking
    • 9.5.10.4. Recent Developments/ Strategic Initiatives
  • 9.5.11. Pfizer Inc.
    • 9.5.11.1. Participant's Overview
    • 9.5.11.2. Financial Performance
    • 9.5.11.3. Product Benchmarking
    • 9.5.11.4. Recent Developments/ Strategic Initiatives
  • 9.5.12. Takeda Pharmaceutical Company Limited
    • 9.5.12.1. Participant's Overview
    • 9.5.12.2. Financial Performance
    • 9.5.12.3. Product Benchmarking
    • 9.5.12.4. Recent Developments/ Strategic Initiatives